NSC 33994Selective JAK2 inhibitor CAS# 82058-16-0 |
- Tenovin-1
Catalog No.:BCC2239
CAS No.:380315-80-0
- PRIMA-1MET
Catalog No.:BCC2414
CAS No.:5291-32-7
- PRIMA-1
Catalog No.:BCC2413
CAS No.:5608-24-2
- Pifithrin-α (PFTα)
Catalog No.:BCC2241
CAS No.:63208-82-2
- MIRA-1
Catalog No.:BCC2409
CAS No.:72835-26-8
- JNJ-26854165 (Serdemetan)
Catalog No.:BCC2240
CAS No.:881202-45-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 82058-16-0 | SDF | Download SDF |
PubChem ID | 5473838 | Appearance | Powder |
Formula | C28H42N2O2 | M.Wt | 438.65 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 5 mM in DMSO with gentle warming and to 10 mM in ethanol with gentle warming | ||
Chemical Name | 2-(diethylaminomethyl)-4-[(E)-4-[3-(diethylaminomethyl)-4-hydroxyphenyl]hex-3-en-3-yl]phenol | ||
SMILES | CCC(=C(CC)C1=CC(=C(C=C1)O)CN(CC)CC)C2=CC(=C(C=C2)O)CN(CC)CC | ||
Standard InChIKey | QFNJFVBKASKGEU-OCEACIFDSA-N | ||
Standard InChI | InChI=1S/C28H42N2O2/c1-7-25(21-13-15-27(31)23(17-21)19-29(9-3)10-4)26(8-2)22-14-16-28(32)24(18-22)20-30(11-5)12-6/h13-18,31-32H,7-12,19-20H2,1-6H3/b26-25+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective inhibitor of JAK2 (IC50 = 60 nM). Displays no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM. |
NSC 33994 Dilution Calculator
NSC 33994 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2797 mL | 11.3986 mL | 22.7972 mL | 45.5944 mL | 56.993 mL |
5 mM | 0.4559 mL | 2.2797 mL | 4.5594 mL | 9.1189 mL | 11.3986 mL |
10 mM | 0.228 mL | 1.1399 mL | 2.2797 mL | 4.5594 mL | 5.6993 mL |
50 mM | 0.0456 mL | 0.228 mL | 0.4559 mL | 0.9119 mL | 1.1399 mL |
100 mM | 0.0228 mL | 0.114 mL | 0.228 mL | 0.4559 mL | 0.5699 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Selective inhibitor of JAK2 (IC50 = 60 nM). Displays no effect on Src and TYK2 tyrosine kinase activity at a concentration of 25 μM.
- Loteprednol etabonate
Catalog No.:BCC4916
CAS No.:82034-46-6
- Boc-Leucinol
Catalog No.:BCC2724
CAS No.:82010-31-9
- 10Z-Hymenialdisine
Catalog No.:BCC5773
CAS No.:82005-12-7
- Daurichromenic acid
Catalog No.:BCN4355
CAS No.:82003-90-5
- 8-Anilino-1-naphthalenesulfonic acid
Catalog No.:BCC8785
CAS No.:82-76-8
- Peri acid
Catalog No.:BCC9116
CAS No.:82-75-7
- Visnagin
Catalog No.:BCN4367
CAS No.:82-57-5
- 1-Amino-2-methylanthraquinone
Catalog No.:BCC8451
CAS No.:82-28-0
- Alpha-Toxicarol
Catalog No.:BCN6467
CAS No.:82-09-7
- Rottlerin
Catalog No.:BCC7127
CAS No.:82-08-6
- Benzanthrone
Catalog No.:BCC8845
CAS No.:82-05-3
- Khellin
Catalog No.:BCN4356
CAS No.:82-02-0
- JNJ 17203212
Catalog No.:BCC7668
CAS No.:821768-06-3
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
- FMK
Catalog No.:BCC1580
CAS No.:821794-92-7
- Andropanoside
Catalog No.:BCN4570
CAS No.:82209-72-1
- Andrographiside
Catalog No.:BCN4569
CAS No.:82209-76-5
- Atomoxetine HCl
Catalog No.:BCC5046
CAS No.:82248-59-7
- Impurity C of Alfacalcidol
Catalog No.:BCC5385
CAS No.:82266-85-1
- Breyniaionoside A
Catalog No.:BCN7112
CAS No.:823182-23-6
- Styraxlignolide F
Catalog No.:BCN3416
CAS No.:823214-06-8
- SN 2
Catalog No.:BCC6325
CAS No.:823218-99-1
- Coelonin
Catalog No.:BCN3600
CAS No.:82344-82-9
- Heliocoromandaline
Catalog No.:BCN2046
CAS No.:82354-33-4
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.[Pubmed:19447617]
Bioorg Med Chem Lett. 2009 Jul 1;19(13):3598-601.
Janus kinase 2 (JAK2) plays a crucial role in the pathomechanism of myeloproliferative disorders and hematologic malignancies. A somatic mutation of JAK2 (Val617Phe) was previously shown to occur in 98% of patients with polycythemia vera and 50% of patients with essential thrombocythemia and primary myelofibrosis. Thus, effective JAK2 kinase inhibitors may be of significant therapeutic importance. Here, we applied a structure-based virtual screen to identify novel JAK2 inhibitors. One JAK2 inhibitor in particular, G6, demonstrated remarkable potency as well as specificity, which makes it as a potential lead candidate against diseases related to elevated JAK2 tyrosine kinase activity.